Halozyme Therapeutics, Inc. reiterating earnings guidance for the year 2022. For the year, the company expects net revenue to be in the range of $530 million to $560 million, GAAP operating income to be in the range of $350 million to $380 million, GAAP net income to be in the range of $270 million to $295 million and GAAP diluted EPS to be in the range of $1.90 to $2.05.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.82 USD | -0.53% | -3.81% | +2.33% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.33% | 4.83B | |
-3.30% | 102B | |
+1.79% | 96.84B | |
-0.44% | 21.48B | |
-18.35% | 20.82B | |
-7.45% | 18.6B | |
-40.31% | 16.81B | |
-26.84% | 13.78B | |
+0.59% | 13.4B | |
+20.86% | 11.06B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2022